Immunic Closes $5.1 Million Direct Offering Led by Aberdeen Investments

Immunic, Inc., a biotechnology company focused on small molecule therapies for chronic inflammatory and autoimmune diseases, announced the closing of a $5.1 million registered direct offering. Led by Aberdeen Investments, the offering involved the sale of 5,666,667 shares of common stock at $0.90 per share. The transaction was facilitated by Titan Partners Group, a division of American Capital Partners, acting as the sole placement agent.

The funds will support Immunic's clinical trials, operations, and general corporate purposes. This funding effort is part of a broader financial strategy registered under a Form S-3 filed with the SEC. The formalities surrounding this offering align with standard regulatory frameworks for market activities.